The PCI technology, uniquely positioned for the enhancement of endocytosic drug delivery of compounds such as SiRNAs, has been developed at the Institute of Cancer Research at the Norwegian Radium Hospital, the largest centre for cancer research and cancer treatment in Northern Europe. PCI Biotech and the Institute of Cancer Research have signed a partnership agreement on further development of the photochemical internalisation technology. All intellectual property rights belong to PCI Biotech.

PCI Biotech is interested in collaborating with companies having therapeutic molecules which could benefit from the PCI drug delivery technology. Such collaborations could range from joint product development to out-licensing of the PCI technology.